FCI Ophthalmics, Inc. is pleased to launch LacriJet® in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single use injector.
LacriJet® consists of a single use injector handpiece into which a silicone tube is preloaded inside a metallic probe. LacriJet® has been specifically designed to reduce operating time, during intubation and removal of the device. It is indicated for epiphora, congenital nasolacrimal duct obstruction (CNLDO), and canalicular laceration.
Stent innovation is in the FCI DNA
We work in close collaboration with the world’s leading ophthalmic surgeons, to be continuously on the cutting-edge of research, testing and manufacturing of gold standard medical devices that garner unparalleled trust and reliability.